The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
With federal Obamacare subsidies expired, premiums have surged, but ten states are stepping in with their own aid to keep coverage affordable. New Mexico fully replaces the gap for all incomes, while others target low earners amid cost pressures from GLP-1 drugs like Ozempic and Wegovy. Enrollment trends vary, with some states seeing gains despite national drops.
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
GLP-1 medications are reshaping bakery demands, driving growth in high-fiber, high-protein products. Ardent Mills is leading with benefit-stacking strategies using UltraGrain flour and chickpea ingredients to support satiety and digestive health for users. This guide details the research, innovations, and future outlook.
As GLP-1 medications surge in popularity, the Institute of Food Technologists (IFT) is guiding brands on functional foods to fill nutrition gaps. From Danone’s Oikos Fusion yogurt to fiber-woven snacks by Lasso, discover how proteins, prebiotics, and micronutrients support satiety and muscle health for users.
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
Comedian Tanmay Bhat recently opened up about his disappointing experience with GLP-1 medications, reporting zero appetite suppression despite using them for weight management. He attributes this to a BDNF gene variant affecting satiety signaling, sparking discussions on genetic factors in treatment response. While many see benefits from drugs like semaglutide and tirzepatide, Bhat's story highlights why results vary.
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
